Company

HeraMED Limited

Headquarters: Sydney, NSW, Australia

CEO: Mr. David Groberman

ASX: HMD

Market Cap

A$7.7 Million

AUD as of Jan. 1, 2024

US$5.3 Million

Market Cap History

HeraMED Limited market capitalization over time

Evolution of HeraMED Limited market cap in the past 5 years

Market capitalizations are calculated from the opening stock price at the beginning of each month.

Market Cap History of HeraMED Limited

Detailed Description

HeraMED Limited, together with its subsidiaries, operates as a medical technology company. It develops, manufactures, and sells foetal heart beat monitors and other pregnancy monitoring solutions for home use in Australia, Europe, and Israel. The company provides HeraBEAT, a fetal heart rate monitor principally for use by an expectant mother to monitor their fetus' heartbeat. It is also involved in developing EchoBEAT, the next generation of its home-oriented pregnancy monitoring devices; and Orion, an artificial intelligence powered pregnancy monitoring system for pregnancy monitoring analysis. The company has a collaboration agreement with Mayo Clinic for the development of its HeraCARE pregnancy management platform. HeraMED Limited was incorporated in 2011 and is headquartered in Netanya, Israel.

Top 1-year algo backtest: +284.14%

$10,000 in April 2023 would now be $38,414 by following this algorithm daily at market close.

Boost your stocks returns with Disfold AI... Now!

Try Disfold AI for FREE

Stocks & Indices

HeraMED Limited has the following listings and related stock indices.


Stock: ASX: HMD wb_incandescent

Details

Headquarters:

23-25 Hunter Street

Suite 3 Level 10

Sydney, NSW 2000

Australia

Phone: 61 2 8379 2961